Papers of particular interest, published within the annual period of review, have been highlighted as:
1. US Burden of Disease Collaborators. The state of US health, 1990–2010: burden of diseases, injuries, and risk factors. J Am Med Assoc 2013; 310:591–608.
3. Juniper M, Le T, Mladsi D. The epidemiology, economic burden, and pharmacological treatment of chronic low back pain in France, Germany, Italy, Spain and the UK: a literature-based review. Expert Opin Pharmacother 2009; 10:2581–2592.
4. Crow W, Willis D. Estimating cost of care for patients with acute low back pain: a retrospective review of patient records. J Am Osteopath Assoc 2009; 109:229–233.
5▪▪. Cohen SP, Mao J. Mechanisms of neuropathic pain
and their clinical implications. Br Med J 2014; 348:f7656.
In-depth and detailed review of neuropathic pain mechanisms and potential pharmacologic targets.
6. Freynhagen R, Baron R, Gockel U, et al. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006; 22:1911–1920.
7. Bennett MI, Smith BH, Torrance N, et al. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain 2005; 6:149–158.
8▪▪. Hsu E, Murphy S, Chang D, Cohen S. Expert opinion on emerging drugs: chronic low back pain. Expert Opin Emerg Drugs 2015; 20:103–127.
Review of available and developmental pain therapeutic compounds, as well as discussion of barriers to market entry.
9. Woolf CJ, Max MB. Mechanism-based pain diagnosis: issues for analgesic drug development. Anesthesiology 2001; 95:241–249.
10. Bouhassira D, Lantéri-Minet M, Attal N, et al. Prevalence of chronic pain
with neuropathic characteristics in the general population. Pain 2008; 136:380–387.
11. Harifi G, Amine M, Ait Ouazar M, et al. Prevalence of chronic pain
with neuropathic characteristics in the Moroccan general population: a national survey. Pain Med 2013; 14:287–292.
12. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain
of predominantly neuropathic origin. Results from a general population survey. J Pain 2006; 7:281–289.
13. Hopewell S, Loudon K, Clarke MJ, et al. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev 2009; MR000006.
14. Farrar JT. What is clinically meaningful: outcome measures in pain clinical trials. Clin J Pain 2000; 16 (2 Suppl):S106–S112.
15. Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain
in adults. Cochrane Database Syst Rev 2012; 7:CD008943.
16. Pande AC, Pyke RE, Greiner M, et al. Analgesic efficacy of enadoline versus placebo or morphine in postsurgical pain. J Clin Neuropharm 1996; 19:451–456.
17. Riviere PJM. Peripheral kappa-opioid agonists for visceral pain. Br J of Pharm 2004; 141:1331–1334.
19. Arendt-Nielsen L, Olesen AE, Staahl C, et al. Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multimodal, multitissue experimental human pain model: selective effect on visceral pain. Anesthesiology 2009; 111:616–624.
20. Gan TJ, Jones JB, Schuller R, et al. Analgesic and morphine-sparing effects of the peripherally-restricted kappa opioid agonist CR845 after intravenous administration in women undergoing a laparoscopic hysterectomy. Anesth Analg 2013; 116:S1.
21. Vanderah TW, Gardell LR, Burgess SE, et al. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci 2000; 20:7074–7079.
22. Pergolizzi J, Aloisi AM, Dahan A, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract 2010; 10:428–450.
23. Koppert W, Ihmsen H, Korber N, et al. Different profiles of buprenorphine-induced analgesia
and antihyperalgesia in a human pain model. Pain 2005; 118:15–22.
24. Constantino CM, Gomes I, Stockton SD, et al. Opioid receptor heteromers in analgesia
. Exp Rev Mol Med 2012; 14:e9.
25▪. Ong EW, Cahill CM. Molecular perspectives for mu/delta opioid receptor heteromers as distinct, functional receptors. Cells 2014; 3:152–179.
Detailed overview of mu/delta opioid receptor heteromer as a functionally distinct receptor and potential analgesic target.
26. Cahill CM, Morinville A, Lee MC, et al. Prolonged morphine treatment targets delta opioid receptors to neuronal plasma membranes and enhances delta-mediated antinociception. J Neurosci 2001; 21:7598–7607.
27. Mollereau C, Parmentier M, Mailleux P, et al. ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett 1994; 341:33–38.
28. Reinscheid RK, Nothacker HP, Bourson A, et al. Orphanin FQ: a neuropeptide that activates an opioid-like G protein-coupled receptor. Science 1995; 270:792–794.
29. Meunier JC, Mollereau C, Toll L, et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 1995; 377:532–535.
30. Mogil JS, Pasternak GW. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol Rev 2001; 53:381–415.
31. Lambert DG. The nociception/orphanin FQ receptor: a target with broad therapeutic potential. Nature Rev 2008; 7:694–710.
32. Hawes BE, Graziano MP, Lambert DG. Cellular actions of nociceptin: transduction mechanisms. Peptides 2000; 21:961–967.
33. New DC, Wong YH. The ORL1 receptor: molecular pharmacology and signaling mechanisms. Neurosignals 2002; 11:197–212.
34. Knoflach F, Reinscheid RK, Civelli O, Kemp JA. Modulation of voltage-gated calcium channels by orphanin FQ in freshly dissociated hippocampal neurons. J Neurosci 1996; 16:6657–6664.
35. Vaughn CW, Christy MJ. Increase by the ORL1 receptor (opioid receptor-like 1) ligand, nociception of inwardly rectifying K conductance in dorsal raphe nucleus neurons. Br J Pharmacol 1996; 117:1609–1611.
36. Nicol B, Lambert DG, Rowbotham DJ, et al. Nociceptin induced inhibition of K+ evoked glutamate release from rat cerebrocortical slices. Br J Pharmacol 1996; 119:1081–1083.
37. Marti M, Stocchi S, Paganini F, et al. Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex. Br J Pharmacol 2003; 138:91–98.
38. Giuliani S, Maggi CA. Inhibition of tachykinin release from peripheral endings of sensory nerves by nociceptin, a novel opioid peptide. Br J Pharmacol 1996; 118:1567–1569.
39. Rizzi A, Nazzaro C, Marzola GG, et al. Endogenous nociceptin/orphanin FQ signaling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: pharmacological and genetic evidences. Pain 2006; 124:100–108.
40. Zeilhofer HU, Calo G. Nociceptin/orphanin FQ and its receptor: potential targets for pain therapy? J Pharmacol Exp Ther 2003; 306:423–429.
41. Pan Z, Hirakawa N, Fields HL. A cellular mechanism for the bidirectional pain-modulating actions of orphanin FQ/nociceptin. Neuron 2000; 26:515–522.
42. King MA, Rossi GC, Chang AH, et al. Spinal analgesic activity of orphanin FQ/nociceptin and its fragments. Neurosci Lett 1997; 223:113–116.
43. Ko MC, Wei H, Woods JH, Kennedy RT. Effects of intrathecally administered nociceptin/orphanin FQ in monkeys: behavioral and mass spectrometric studies. J Pharmacol Exp Ther 2006; 318:1257–1264.
44. Inoue M, Kawashima T, Takeshima H, et al. In vivo pain-inhibitory role of nociceptin/orphanin FQ in spinal cord. J Pharmacol Exp Ther 2003; 305:495–501.
45. Erb K, Liebel JT, Tegeder I, et al. Spinally delivered nociception/orphanin FQ reduces flinching behaviour in the rat formalin test. Neuroreport 1997; 8:1967–1970.
46. Yamamoto T, Nozaki-Taguchi N, Kimura Sl. Analgesic effect of intrathecally administered nociception, an opioid receptor-like 1 receptor agonist, in the rat formalin test. Neuroscience 1997; 81:249–254.
47. Ko MC, Naughton NN, Traynor JR, et al. Orphanin FQ inhibits capsaicin-induced thermal nociception in monkeys by activation of peripheral ORL1 receptors. Br J Pharmacol 2002; 135:943–950.
48. Obara I, Przewlocki R, Przewlocki B. Spinal and local peripheral antiallodynic activity of Ro64-6198 in neuropathic pain
in the rat. Pain 2005; 116:17–25.
49. Kolesnikov YA, Pasternak GW. Peripheral orphanin FQ/nociceptin analgesia
in the mouse. Life Sci 1999; 64:2021–2028.
50. Schoblock JR. The pharmacology of Ro 64-6198, a systemically active, nonpeptide NOP receptor (opiate receptor-like 1, ORL-1) agonist with diverse preclinical therapeutic activity. CNS Drug Rev 2007; 13:107–136.
51. Ueda H, Yamaguchi T, Tokuyama S, et al. Partial loss of tolerance liability to morphine analgesia
in mice lacking the nociceptin receptor gene. Neurosci Lett 1997; 237:136–138.
52. Ueda H, Inoue M, Takeshima H, Iwasawa Y. Enhanced spinal nociceptin receptor expression develops morphine tolerance and dependence. J Neurosci 2000; 20:7640–7647.
53. Chung S, Pohl S, Zeng J, et al. Endogenous orphanin FQ/nociceptin is involved in the development of morphine tolerance. J Pharmacol Exp Ther 2006; 318:262–267.
54. Rizzi A, Bigoni R, Marzola G, et al. The nociceptin/orphanin FQ receptor antagonist, [Nphe1]NC(1-13)NH2, potentiates morphine analgesia
. Neuroreport 2002; 11:2369–2372.
55. Bloms-Funke P, Gillen C, Schuettler AJ, et al. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides 2000; 21:1141–1146.
56. Yamamoto T, Shono K, Tanabe S. Buprenorphine activates mu and opioid receptor like-1 receptors simultaneously, but the analgesic effect is mainly mediated by m receptor activation in the rat formalin test. J Pharmacol Exp Ther 2006; 318:206–213.
57▪. Lambert DG, Bird MF, Rowbotham DJ. Cebranopadol: a first in-class example of a nociceptin/orphanin FQ receptor and opioid receptor agonist. Br J Anaesth 2015; 114:364–366.
Concise overview of preclinical and clinical data regarding cebranopadol in the treatment of a variety of pain conditions.
58. Marks DM, Shah MJ, Patkar AA, et al. Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise. Curr Neuropharmacol 2009; 7:331–336.
59. Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. J Clin Inv 2010; 120:3779–3787.
60. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain
: a Cochrane review. J Neurol Neurosurg Psychiatry 2010; 81:1372–1373.
61▪▪. Moulin DE, Boulanger A, Clark AJ, et al. Pharmacological management of chronic neuropathic pain
: revised consensus statement from the Canadian Pain Society. Pain Res Manag 2014; 19:328–335.
Comprehensive review of randomized controlled trials and systematic reviews related to the pharmacological management of neuropathic pain.
62. Verdu B, Decosterd I, Buclin T, et al. Antidepressants for the treatment of chronic pain
. Drugs 2008; 68:2611–2632.
63. Chou R. Low back pain (chronic). BMJ Clin Evid 2010; 2010:1116.
64. Skljarevski V, Ossanna M, Liu-Seifert H, et al. A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol 2009; 16:1041–1048.
65. Skljarevski V, Desaiah D, Liu-Seifert H, et al. Efficacy and safety of duloxetine in patients with chronic low back pain. Spine 2010; 35:E578–E585.
66. Skljarevski V, Zhang S, Desaiah D, et al. Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial. J Pain 2010; 11:1282–1290.
67. Chappell AS, Ossanna MJ, Liu-Seifert H, et al. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial. Pain 2009; 146:253–260.
68. Chappell AS, Desaiah D, Liu-Seifert H, et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain
due to osteoarthritis of the knee. Pain Pract 2011; 11:33–41.
69. Frakes EP, Risser RC, Ball TD, et al. Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011; 27:2361–2372.
70. Sommer C, Hauser W, Alten R, et al. Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline. Schmerz 2012; 26:297–310.
71. Choy E, Marshall D, Gabriel ZL, et al. A Systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. Semin Arth Rheum 2011; 41:335–345.
72. Cannon KE, Chazot PL, Hann V, et al. Immunohistochemical localization of histamine H3 receptors in rodent skin, dorsal root ganglia, superior cervical ganglia, and spinal cord: potential antinociceptive targets. Pain 2007; 129:76–92.
73. Kajihara Y, Murakami M, Imagawa T, et al. Histamine potentiates acid-induced responses mediating transient receptor potential V1 in mouse primary sensory neurons. Neuroscience 2010; 166:292–304.
74. Cannon KE, Nalwalk JW, Stadel R, et al. Activation of spinal histamine H3 receptors inhibits mechanical nociception. Eur J Pharmacol 2003; 470:139–147.
75. Cannon KE, Leurs R, Hough LB. Activation of peripheral and spinal histamine H3 receptors inhibits formalin-induced inflammation and nociception, respectively. Pharmacol Biochem Behav 2007; 88:122–129.
76. Lindsay B, Hough, Frank L. Rice. H3 receptors and pain modulation: peripheral, spinal, and brain interactions. Center for Neuropharmacology and Neuroscience: Albany Medical College, Albany, New York; 2010.
77. Glick SD, Crane LA. Opiate-like and abstinence-like effects of intracerebral histamine administration in rats. Nature 1978; 273:547–549.
78. Gogas KR, Hough LB, Eberle NB, et al. A role for histamine and H2-receptors in opioid antinociception. J Pharmacol Exp Ther 1989; 250:476–484.
79. Vollinga RC, de Koning JP, Jansen FP, et al. A new potent and selective histamine H3 receptor agonist, 4-(1H-imidazol- 4-ylmethyl)piperidine. J Med Chem 1994; 37:332–333.
80. Arrang JM, Garbarg M, Lancelot JC, et al. Highly potent and selective ligands for histamine H3-receptors. Nature 1987; 327:117–123.
81. Medhurst SJ, Collins SD, Billinton A, et al. Novel histamine H3 receptor antagonists GSK189254 and GSK334429 are efficacious in surgically-induced and virally- induced rat models of neuropathic pain
. Pain 2008; 138:61–69.
82. Huang L, Adachi N, Nagaro T, et al. Histaminergic involvement in neuropathic pain
produced by partial ligation of the sciatic nerve in rats. Reg Anesth Pain Med 2007; 32:124–129.
83. Hsieh GC, Honore P, Pai M, et al. Antinociceptive effects of histamine H3 receptor antagonist in the preclinical models of pain in rats and the involvement of central noradrenergic systems. Brain Res 2010; 1354:74–84.
84. Gemkow MJ, Davenport AJ, Harich S, et al. The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discov Today 2009; 14:509–515.
85. Khan ZP, Ferguson CN, Jones RM. Alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Anaesthesia 1999; 54:146–165.
86. Chan AK, Cheung CW, Chong YK. Alpha-2 agonists in acute pain management. Expert Opin Pharmacother 2010; 11:2849–2868.
87. Loveridge R, Patel S. Systemic nonopioid adjuvant analgesics: their role in acute postoperative pain in adults. Trends Anaesth Crit Care 2014; 4:10–18.
88. Aley KO, Levine JD. Multiple receptors involved in the peripheral alpha 2, mu and A1 antinociception, tolerance and withdrawal. Neurosci 1997; 17:735–744.
89. Budai D, Harasawa I, Fields HL. Midbrain periaqueductal gray (PAG) inhibits nociceptive inputs to sacral dorsal horn nociceptive neurons through alpha2-adrenergic receptors. J Neurophysiol 1998; 80:2244–2254.
90. Davis KD, Treede RD, Raja SN, et al. Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain. Pain 1991; 47:309–317.
91. Eisenach JC, De Kock M, Klimscha W. [alpha]2-adrenergic agonists for regional anesthesia: a clinical review of clonidine (1984–1995). Anesthesiology 1996; 85:655–674.
92. Cohen SP, Dragovich A. Intrathecal analgesia
. Med Clin N Am 2007; 91:251–270.
93. Siddall PJ, Molloy AR, Walker S, et al. The efficacy of intrathecal morphine and clonidine in the treatment of pain after spinal cord injury. Anesth Analg 2000; 91:1493–1498.
94. Ackerman LL, Follett KA, Rosenquist RW. Long-term outcomes during treatment of chronic pain
with intrathecal clonidine or clonidine/opioid combinations. J Pain Symptom Manage 2003; 26:668–677.
95. Deer T, Krames ES, Hassenbusch SJ, et al. Polyanalgesic consensus conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2007; 10:300–328.
96▪. Kumar A, Maitra S, Khanna P, Baidya DK. Clonidine for management of chronic pain
: a brief review of the current evidences. Saudi J Anaesth 2014; 8:92–96.
Qualitative analysis of 30 clinical studies of clonidine use in the treatment of chronic neuropathic pain.
97. Elhakim M, Abdelhamid D, Abdelfattach H, et al. Effect if epidural dexmedetomidine on intraoperative awareness and postoperative pain after one-lung ventilation. Acta Anaesth Scand 2010; 54:703–709.
98. Kanazi GE, Aouad MT, Jabbour-Khoury SI, et al. Effect of low-dose dexmedetomodine or clonidine on the characteristics of bupivacaine spinal block. Acta Anaesth Scand 2006; 50:222–227.
99. Esmaoglu A, Mizrak A, Akin A, et al. Addition of dexmedetomidine to lidocaine for intravenous regional anaesthesia. Eur J Anaesthesiol 2005; 22:447–451.
100. Adams IB. Cannabis pharmacology and toxicology in animals and humans. Addiction 1996; 91:1585–1614.
101. Geller T. Cannabinoids: a secret history. Chem Heritage News Magazine 2007; 25.
102. Naef M, Curatolo M, Petersen-Felix S, et al. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine and a THC-morphine combination in healthy patients under experimental pain conditions. Pain 2003; 105:78–79.
103. Kraft B, Frickey NA, Kaufmann RM, et al. Lack of analgesia
by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology 2008; 109:101–110.
104. Wallace M, Schulteis G, Atkinson JH, et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 2007; 107:785–796.
105. Beaulieu P. Effects of nabilone, a synthetic cannabinoid on postoperative pain. Can J Anaesth 2006; 53:765–769.
106. Lynch ME, Campbell F. Cannabinoids for treatment of chronic noncancer pain; a systematic review of randomized trials. Br J Clin Pharm 2011; 72:735–744.
107. Martin-Sanchez E, Furukawa TA, Taylor J, Martin JL. Systematic review and meta-analysis of cannabis treatment for chronic pain
. Pain Med 2009; 10:101353–101368.
108. Henquet C, Krabbendam L, Spauwen J, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. Br Med J 2005; 330:11.
109. Leweke FM, Koethe D. Cannabis and psychiatric disorders: it is not only addiction. Addict Biol 2008; 13:264–275.
110. Kraft B. Is there any clinically relevant cannabinoid-induced analgesia
? Pharmacology 2012; 89:237–246.
111. Atwood BK, Wager-Miller J, Haskins C, et al. Functional selectivity in CB2 cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB2 ligands. Mol Pharmacol 2012; 81:250–263.
112. Maresz K, Pryce G, Ponomarev ED, et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 2007; 13:492–497.
113. Felder CC, Joyce KE, Briley EM, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharm 1995; 48:443–450.
114. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54:161–220.
115. Kano M, Ohno-Shosaku T, Hashimotodani Y, et al. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 2009; 89:309–380.
116. Anand P, Whiteside G, Fowler CJ, Hohmann AG. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev 2009; 60:255–266.
117. Sokal DM, Elmes SJ, Kendall DA, Chapman V. Intraplantar injection of anadamide inhibits mechanically-evoked responses of spinal neurons via activation of CB2 receptors in anaesthetised rats. Neurpharm 2003; 45:404–411.
118. Katona I, Freund TF. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nature Med 2008; 14:923–930.
119. Piet R, Garenne A, Farrugia F, et al. State-dependent, bidirectional modulation of neural network activity by endocannabinoids. J Neurosci 2011; 31:16591–16596.
120. Kato A, Punnakkal P, Pernía-Andrade AJ, et al. Endocannabinoid-dependent plasticity at spinal nociceptor synapses. J Physiol 2012; 590:4717–4733.
121. Lim G, Sung B, Ji RR, Mao J. Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain
behaviors in rats. Pain 2003; 105:275–283.
122▪. Davis MP. Cannabinoids in pain management: CB1, CB2 and nonclassic receptor ligands. Expert Opin Investig Drugs 2014; 23:1123–1140.
Overview of the endogenous cannabinoid system and its potential therapeutic targets.
123. Kalliomaki J, Annas P, Huizar K, et al. Evaluation of the analgesic efficacy and psychoactive effects of AZD1940, a novel peripherally acting cannabinoid agonist, in human capsaicin-induced pain and hyperalgesia. Clin Exp Pharmacol Physiol 2013; 40:212–218.
124. Maresz K, Carrier EJ, Ponomarev ED, et al. Modulation of the cannabinoids CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 2005; 95:437–445.
125. Zhang J, Hoffert C, Vu HK, et al. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain
models. Eur J Neurosci 2003; 17:2750–2754.
126. den Boon FS, Chameau P, Schaafsma-Zhao Q, et al. Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors. Proc Natl Acad Sci USA 2012; 109:3534–3539.
127. Ibrahim MM, Deng H, Zvonok A, et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain
: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci 2003; 100:10529–10533.
128. Ibrahim MM, Rude ML, Stagg NJ, et al. CB2 cannabinoid receptor mediation of antinociception. Pain 2006; 122:36–42.
129. Elmes SJ, Jhaveri MD, Smart D, et al. Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naïve rats and in rat models of inflammatory and neuropathic pain
. Eur J Neurosci 2004; 20:2311–2320.
130. Sagar DR, Kelly S, Millns PJ, et al. Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur J Neurosci 2005; 22:371–379.
131. Riether D. Selective cannabinoid receptor 2 modulators: a patent review 2009-present. Expert Opin Ther Pat 2012; 22:495–510.
132. Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonylglycerol. Chem Biol 2007; 14:1347–1356.
133. Long JZ, Li W, Booker L, et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 2009; 5:37–44.
134. Croci T, Zarini E. Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats. Br J Pharmacol 2007; 150:559–566.
135▪. Ueda M, Iwasaki H, Wang S, et al. Cannabinoid receptor type 1 antagonist, AM251, attenuates mechanical allodynia and thermal hyperalgesia after burn injury. Anesthesiology 2014; 121:1311–1319.
Describes a possible role of CB1 antagonism in treating burn injury induced allodynia and hyperalgesia.
136. Szallasi A, Blumberg PM. [3H]resiniferatoxin binding by the vanilloid receptor species-related differences, effects of temperature and sulhydryl reagents. Naunyn-Schmiedebergs Arch Pharmacol 1993; 347:84–91.
137. Szallasi A, Blumberg PM. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev 1999; 51:159–212.
138. Immke DC, Gavva NR. The TRPV1 receptor and nociception. Semin Cell Dev Biol 2006; 17:582–591.
139. Szallasi A, Cortright DN, Blum CA, Eid SR. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nature Rev Drug Discov 2007; 6:357–372.
140. Cortright DN, Szallasi A. Biochemical pharmacology of the vaniloid receptor TPRV1. An update. Eur J Biochem 2004; 271:1814–1819.
141. Gunthorpe MJ, Benham CD, Randall A, Davis JB. The diversity in the vanilloid (TRPV) receptor family of ion channels. Trends Pharmacol Sci 2002; 23:183–191.
142. Starowicz K, Nigam S, Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 2007; 114:13–33.
143. Holzer P. TRPV1 and the gut: from a tasty receptor for a painful vanilloid to a key player in hyperalgesia. Eur J Pharmacol 2004; 500:231–234.
144. Ji RR, Samad TA, Jin SX, et al. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002; 36:57–68.
145. Keeble J, Russell F, Curtis B, et al. Involvement of transient receptor potential vanilloid 1 in the vascular and hyperalgesic components of joint inflammation. Arthr Rheumatol 2005; 52:3248–3256.
146. Szolcsanyi J. Forty years in capsaicin research for sensory pharmacology and physiology. Neuopeptides 2004; 32:377–384.
147. Caterina MJ. Transient receptor potential ion channels as participants in thermosensation and thermoregulation. Am J Physiol Regulat Integr Comparat Physiol 2000; 292:R64–R76.
148. Davis JB, Gray J, Gunthorpe MJ, et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 2000; 405:183–187.
149. Menendez L, Juárez L, García E, et al. Analgesic effects of capasazepine and resiniferatoxin on bone cancer pain in mice. Neurosci Lett 2006; 393:70–73.
150. Knotkova H, Pappagallo M, Szallasi A. Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival? Clin J Pain 2008; 24:142–154.
151. Wong GY, Gavva NR. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: recent advances and setbacks. Brain Res Rev 2009; 60:267–277.
152. Cantillon M, Tagoe M, Vause E, et al. Safety, tolerability and efficacy of intraoperative ALGRX 4975 in a randomized, double-blind, placebo-controlled study of subjects undergoing bunionectomy. J Pain 2005; 6:S48.
153. Diamond E, Miller T. ALGRX 4975 reduces pain of intermetatarsal neuroma: preliminary results from a randomized, double-blind, placebo-controlled, phase II multicenter clinical trial. J Pain 2006; 7:S41.
154. Richards P, Stasko VG, Lacko I, et al. ALGRX 4975 reduces pain of acute lateral epicondylitis: preliminary results from a randomized, double-blind, placebo-controlled, phase II multicenter clinical trial. J Pain 2006; 7:S3.
155. Cantillon M, Vause E, Sykes D, et al. Safety, tolerability and efficacy of ALGRX 4975 in osteoarthritis (OA) of the knee. J Pain 2005; 6:S39.
156▪. Lee Y, Hong S, Cui M, et al. Transient receptor potential vanilloid type 1 antagonists: a patent review (2011–2014). Expert Opin Ther Pat 2015; 25:291–318.
Review of TRPV1 antagonists in development, includes preclinical and clinical data.
157. Gunthrope MJ, Chizh BA. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway. Drug Discov Today 2009; 14:56–67.
158. Treviasani M, Gatti R. TRPV1 antagonists as analgesic agents. Open Pain J 2013; 6 (S1):108–118.
159. Gavva NR, Treanor JJ, Garami A, et al. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 2008; 136:202–210.
160. Othman AA, Nothaft W, Awni WM, Dutta S. Pharmacokinetics of the TRPV1 antagonist ABT-102 in healthy human volunteers: population analysis of data from 3 phase 1 trials. J Clin Pharmacol 2012; 52:1028–1041.
161. Rowbotham MC, Nothaft W, Duan WR, et al. Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial. Pain 2011; 152:1192–1200.
162. Nash MS, McIntyre P, Groarke A, et al. BCTP, a classic polymodal inhibitor of TRPV1 with a reduced liability for hyperthermia, is analgesic and ameliorates visceral hypersensitivity. J Pharmacol Exp Ther 2012; 342:389–398.
163. Watabiki T, Kiso T, Kuramochi T, et al. Amerljoiration of neuropathic pain
by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect. J Pharmacol Exp Ther 2011; 336:743–750.
164. Benzon HT, Raja SN, Liu SS, et al.. Essentials of pain medicine, 3rd ed. Philadelphia: Elsevier; 2011.
165. Chizh BA, Headley PM. NMDA antagonists and neuropathic pain
: multiple drug targets and multiple uses. Curr Pharm Des 2005; 11:2977–2994.
166. Childers WE, Baudy RB. N-Methyl-D-aspartate antagonists and neuropathic pain
: the search for relief. J Med Chem 2007; 50:2557–2566.
167. Laube B, Kuhse J, Betz H. Evidence for a tetrameric structure of recombinant NMDA receptors. J Neurosci 1998; 18:2954–2961.
168. Kristensen JD, Svensson B, Gordh T Jr. The NMDA-receptor antagonist CPP abolishes neurogenic ‘wind-up pain’ after intrathecal administration in humans. Pain 1992; 51:249–253.
169. Jones MW, McClean M, Parsons CG, Headley PM. The in vivo relevance of the varied channel-blocking properties of uncompetitive NMDA antagonists: tests on spinal neurons. Neuropharmacology 2001; 41:50–61.
170. McQuay HJ, Carroll D, Jadad AR, et al. Dextramethorphan for the treatment of neuropathic pain
: a double-blind randomized controlled crossover trial with integral n-of-1 design. Pain 1994; 59:127–133.
171. Nelson KA, Park KM, Robinovitz E, et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997; 48:1212–1218.
172. Nikolajsen L, Gottrup H, Kristensen AG, Jensen TS. Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain
after amputation or surgery: a randomized double-blinded, cross-over study. Anesth Analg 2000; 91:960–966.
173. Sang CN, Booher S, Gilron I, et al. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology 2002; 96:1053–1061.
174. Eisenberg E, Kleiser A, Dortort A, et al. The NMDA (N-methyl-D-aspartate) receptor antagonist memantine in the treatment of postherpetic neuralgia: a double-blind, placebo-controlled study. Eur J Pain 1998; 2:321–327.
175. Maier C, Dertwinkel R, Mansourian N, et al. Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain: results of a randomized double-blinded, placebo-controlled trial. Pain 2003; 103:277–283.
176. Basile AS, Janowsky A, Golembiowska K, et al. Characterization of the antinociceptive actions of bicifadine in models of acute, persistent and chronic pain
. J Pharmacol Exp Ther 2007; 321:1208–1225.
177. Riff D, Huang N, Czobor P, Stern W. A five-day, multicenter, randomized, placebo-controlled, double-blind, efficacy and safety study of bicifadine and tramadol versus placebo in the treatment of postoperative bunionectomy pain. J Pain 2006; 7:S40.
178. Krieter PA, Gohdes M, Musick TJ, et al. Pharmacokinetics, disposition, and metabolism of bicifadine in humans. Drug Metab Dispos 2008; 36:252–259.
179. Czobor P, Skolnick P. The secrets of a successful clinical trial: compliance, compliance, compliance. Mol Intervent 2011; 11:107–110.
180. Parsons CG. NMDA receptors as targets for drug action in neuropathic pain
. Eur J Pharmacol 2001; 429:71–78.
181. Chizh BA, Headley PM, Tzschentke TM. NMDA receptor antagonists as analgesics: focus on the NR2B subtype. Trends Pharmcol Sci 2001; 22:636–642.
182. Boyce S, Wyatt A, Webb JK, et al. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localization of NR2B subunit in dorsal horn. Neuropharmacology 1999; 38:611–638.
183. Sang CN, Weaver JJ, Jinga L, Wouden J, Saltarelli MD. The NR2B subunit-selective NMDA receptor antagonist, CP-101,606, reduces pain intensity in patients with central and peripheral neuropathic pain
. Program No. 814.9. 2003 Neuroscience Meeting Planner. New Orleans, LA: Society for Neuroscience. (2003)
184. Zhou HY, Chen SR, Pan HL. Targeting N-methyl-D-spartate receptors for treatment of neuropathic pain
. Expert Rev Clin Pharmacol 2011; 4:379–388.
185. Koller M, Urwyler S. Novel N-methyl-D-aspartate receptor antagonists: a review of compounds patented since 2006. Expert Opin Therapeut Patents 2010; 20:1683–1702.
186. Danysz W, Parsons AC. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 1998; 50:597–664.
187. Wallace MS, Rowbotham MC, Katz NP, et al. A randomized, double-blind, placebo controlled trial of a glycine antagonist in neuropathic pain
. Neurology 2002; 59:1694–1700.
188. Jarvis MF, Honore P, Shieh CC, et al. A-83467, a potent and selective Na v 1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. PNAS 2007; 104:8520–8525.
189▪. Lee JH, Park CK, Chen G, et al. A monoclonal antibody that targets a NaV1.7 channel voltage sensor for pain and itch relief. Cell 2014; 6:1393–1404.
Example of a monoclonal antibody approach for the study and targeting of sodium channel isoform NaV1.7.
190. Liu M, Wood JN. The roles of sodium channels in nociception: implications for mechanisms of neuropathic pain
. Pain Med 2011; 12:S93–S99.
191. Hains BC, Klein JP, Saab CY, et al. Upregulation of sodium channel Na v 1.3 and functional involvement in neuronal hyperexcitability associated with central neuropathic pain
after spinal cord injury. J Neurosci 2003; 23:8881–8892.
192. Lindia JA, Köhler MG, Martin WJ, Abbadie C. Relationship between sodium channel Nav1.3 expression and neuropathic pain
behavior in rats. Pain 2005; 117:145–153.
193. Gold MS, Weinreich D, Kim CS, et al. Redistribution of Nav1.8 in uninjured axons enables neuropathic pain
. J Neurosci 2003; 23:158–166.
194. Dong XW, Goregoaker S, Engler H, et al. Small interfering RNA-mediated selective knockdown of Nav1.8 tetrodotoxin resistant sodium channel reverses mechanical allodynua in neuropathic rats. Neurosci 2007; 146:812–821.
195. Cox JJ, Reimann F, Nicholas AK, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature 2006; 444:894–898.
196▪. Jukic M, Kikelj D, Anderluh M. Isoform selective voltage-gated sodium channel modulators and the therapy of pain. Curr Med Chem 2014; 21:164–186.
Small-molecule approach for the study and targeting of specific sodium channel isoforms.
197. Drenth JP, Finley WH, Breedveld GJ, et al. The primary erythermyalgia-susceptibility gene is located on chromosome 2q31-32. Am J Hum Genet 2001; 68:1277–1282.
198. Fertleman CR, Baker MD, Parker KA, et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 2006; 52:767–774.
199. Catteral WA. Structure and regulation of voltage gated Ca2+ channels. Annu Rev Cell Dev Biol 2000; 16:521–555.
200. Cao YQ. Voltage-gated calcium channels and pain. Pain 2006; 126:5–9.
201. Cizkova D, Marsala J, Lukacova N, et al. Localization of N-type Ca2+ channels in the rat spinal cord following chronic constriction nerve injury. Exp Brain Res 2002; 147:456–463.
202. Yaksh TL. Calcium channels as therapeutic targets in neuropathic pain
. J Pain 2006; 7:S13–30.
203. Rauck RL, Wallace MS, Leong MS, et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain
. J Pain Symptom Manage 2006; 31:393–406.
204. Staats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. J Am Med Assoc 2004; 291:63–70.
205. Maier C, Gockel HH, Gruhn K, et al. Increased risk of suicide under intrathecal ziconotide tredatment? A warning. Pain 2010; 152:235–237.
206. Lee M, Snutch T. Z160: a potent and state-dependent, small molecule blocker of N-type calcium channels effective in nonclinical models of neuropathic pain
. J Pain 2013; 14:S71.
207▪▪. Gilron I, Dickenson AH. Emerging drugs for neuropathic pain
. Expert Opin Emerg Drugs 2014; 19:329–341.
Comprehensive literature search of drugs in development for treatment of neuropathic pain.
208. Short G, Lee M, Snutch T. Z944: a first in-class T-type calcium channel blocker effective in nonclinical models of acute and inflammatory pain. J Pain 2013; 14:S71.
209. Rahman W, Dickenson AH. Voltage gated sodium and calcium channel blockers for the treatment of chronic inflammatory pain. Neurosci Lett 2013; 557:19–26.
210. Lembo PM, Grazzini E, Groblewski T, et al. Proenkephalin A gene products activate a new family of sensory neuron-specific GPCRs. Nat Neurosci 2002; 5:201–209.
211▪. Li Z, He SQ, Xu Q, et al. Activation of MrgC receptor inhibits N-type calcium channels in small-diameter primary sensory neurons in mice. Pain 2014; 155:1613–1621.
Describes potential role of Mrg receptor in pain processing.
212. Dong X, Han S, Zylka MJ, et al. A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons. Cell 2001; 106:619–632.
213. Guan Y, Liu Q, Tang Z, et al. Mas-related G-protein-coupled receptors inhibit pathological pain in mice. Proc Natl Acad Sci USA 2010; 107:15933–15938.
214. Cai M, Chen T, Quirion R, Hong Y. The involvement of spinal bovine adrenal medulla 22-like peptide, the proenkephalin derivative, in modulation of nociceptive processing. Eur J Neurosci 2007; 26:1128–1138.
215. Jiang J, Wang D, Zhou X, et al. Effect of Mas-related gene (Mrg) receptors on hyperalgesia in rats with CFA-induced inflammation via direct and indirect mechanisms. Br J Pharmacol 2013; 170:1027–1040.
216. Grazzini E, Puma C, Roy MO, et al. Sensory neuron-specific receptor activation elicits central and peripheral nociceptive effects in rats. Proc Natl Acad Sci USA 2004; 101:7175–7180.
217. Viet CT, Schmidt BL. Biologic mechanisms of oral cancer pain and implications for clinical therapy. J Dent Res 2012; 91:447–453.
218. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human antitumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48:35–45.
219. Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30:2563–2571.
220. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human antitumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50:1400–1411.
221. van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004; 63:508–516.
222. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253–259.
223. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130:478–486.
224. Keystone EC, Schiff MH, Kremer JM, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50:353–363.
225. Callhoff J, Sieper J, Weib A, et al. Efficacy of TNF α blockers in patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis 2014; 0:1–8.
226. Goulabchand R, Mouterde G, Barnetche T, et al. Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis 2014; 73:414–419.
227. Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis 2012; 71 (Suppl II):i2–i45.
228. Olmarker K, Nutu M, Storkson R. Changes in spontaneous behavior in rates exposed to experimental disc herniation are blocked by selective TNF-α inhibition. Spine 2003; 28:1635–1642.
229. Korhonen T, Karppinen J, Paimela L, et al. The treatment of disc-herniation induced sciatica with infliximab: one year follow-up results of FIRST II, a randomized controlled trial. Spine 2006; 31:2759–2766.
230. Genevay S, Viatte S, Finckh A, et al. Adalimumab in severe and acute sciatica: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62:2339–2346.
231. Cohen SP, White RL, Kurihara C, et al. Epidural steroids, etanercept, or saline in subacute sciatica: a multicenter, randomized trial. Ann Intern Med 2012; 156:551–559.
232. Kume K, Amano S, Yamada S. The efficacy and safety of caudal epidural injection with the TNF-alpha antagonist, etanercept, in patients with disc herniation-induced sciatica. Results of a randomized, controlled, 1-month follow-up study. Ann Rheum Dis 2008; 67 (Suppl II):131.
233. Freeman BJ, Ludbrook GL, Hall S, et al. Randomized, double-blind, placebo-controlled, trial of transforaminal epidural etanercept for the treatment of symptomatic lumbar disc herniation. Spine (Phila Pa 1976) 2013; 38:1986–1994.
234. Ohtori S, Miyagi M, Eguchi Y, et al. Epidural administration of spinal nerves with the tumor necrosis factor-α inhibitor, etanercept, compared with dexamethasone for treatment of sciatica in patients with lumbar spinal stenosis: a prospective randomized study. Spine (Phila Pa 1976) 2012; 15:439–444.
235. Gosselin RD, Suter MR, Ru-Rong Ji RR, et al. Glial cells and chronic pain
. Neuroscientist 2010; 16:519–531.
236. Toyomitsu E, Tsuda M, Yamashita T, et al. CCL2 promotes P2X4 receptor trafficking to the cell surface of microglia. Purinergic Signal 2012; 8:301–310.
237. Mika J, Zychowska M, Popiolk-Barczyk K, et al. Importance of glial activation in neuropathic pain
. Eur J Pharmacol 2013; 716:106–119.
238. Tsuda M, Kuboyama K, Inoue T, et al. Behavioral phenotypes of mice lacking purinergic P2X4 receptors in acute and chronic pain
assays. Mol Pain 2009; 5:28.
239. Landry RP, Jacobs VL, Romero-Sandoval EA, et al. Propentoflylline, a CNS glial modulator does not decrease pain in postherpetic neuralgia patients: in vitro evidence for differential responses in human and rodent microglia and macrophages. Exp Neurol 2012; 234:340–350.
240. Martinez V, Szekely B, Lemarie J, et al. The efficacy of a glial inhibitor, minocycline, for preventing persistent pain after lumbar discectomy: a randomized, double-blind, controlled study. Pain 2013; 154:1197–1203.
241. Siedel MF, Herguijuela M, Forkert R, et al. Nerve growth factor in rheumatic diseases. Semin Arthritis Rheum 2010; 40:109–126.
242. Hefti FF, Rosenthal A, Walicke PA, et al. Novel class of pain drugs based on antagonism of nerve growth factor. Trends Pharm Sci 2006; 27:85–91.
243. Watson JJ, Allen SJ, Dawbarn DD, et al. Targeting nerve growth factor in pain. Biodrugs 2008; 22:349–359.
244. Bennett DL, Averill S, Clary DO, et al. Postnatal changes in the expression of the trkA high-affinity NGF receptor in primary sensory neurons. Eur J Neurosci 1996; 8:2204–2208.
245. Bennett DL. Neurotrophic factors: important regulators of nociceptive function. Neuroscientist 2001; 7:13–17.
246▪▪. Bannwarth B, Kostine M. Targeting Nerve Growth Factor (NGF) for Pain Management: What Does the Future Hold for NGF Antagonists? Drugs 2014; 74:619–626.
Detailed account of the clinical development of NGF antagonists including the 2010 FDA hold and subsequent 2012 FDA Arthritis Advisory Committee ruling.
247▪▪. Lewin GR, Lechner SG, Smith ES. Nerve growth factor and nociception: from experimental embryology to new analgesic therapy. Handb Exp Pharmacol 2014; 220:251–282.
Extensive and detailed overview of NGF physiology.
248. Holmes D. Anti-NGF painkillers back on track? Nat Rev Drug Disc 2012; 11:337–338.
249. Owolabi JB, Rizkalla G, Tehim A, et al. Characterization of antiallodynic actions of ALE-0540, a novel nerve growth factor receptor antagonist, in the rat. J Pharm Exp Ther 1999; 289:1271–1276.
250. Winston JH, Toma H, Shenoy M, et al. Acute pancreatitis results in referred mechanical hypersensitivity and neuropeptide up-regulation that can be suppressed by the protein kinase inhibitor K252a. J Pain 2003; 4:329–337.
251. Wong RKS, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database of Syst Rev 2002; 2:CD002068.
252. Wong MH, Stockler MR, Pavlakis N. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2012; 2:CD003474.
253. Mhaskar R, Redzepovic J, Wheatley K, et al. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev 2012; 5:CD003188.
254. Yuen KK, Shelley M, Sze WM, et al. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev 2006; CD006250.
255. Bonabello A, Galmozzi MR, Canaparo R, et al. Long-term analgesic effect of clodronate in rodents. Bone 2003; 33:567–574.
256. Winston MJ, Srivastava T, Jarka D, Alon US. Bisphosphonates for pain management in children with benign cartilage tumors. Clin J Pain 2012; 28:268–272.
257. Yanow J, Pappagallo M, Pillai L. Complex regional pain syndrome (CRPS/RSD) and neuropathic pain
: role of intravenous bisphosphonates as analgesics. ScientificWorldJournal 2008; 8:229–236.
258. Tran DQ, Duong S, Bertini P, Finlayson RJ. Treatment of complex regional pain syndrome: a review of the evidence. Can J Anaesth 2010; 57:149–166.
259. O’Connell NE, Wand BM, McAuley J, et al. Interventions for treating pain and disability in adults with complex regional pain syndrome. Cochrane Database Syst Rev 2011; CD009416.
260. Ohtori S, Akazawa T, Murata Y, et al. Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures. J Clin Neurosci 2010; 17:209–213.
261. Pappagallo M, Breuer B, Lin HM, et al. A pilot trial of intravenous pamidronate for chronic low back pain. Pain 2014; 155:108–117.
262. Morden NE, Munson JC, Smith J, et al. Oral bisphosphonates and upper gastrointestinal toxicity: a study of cancer and early signals of esophageal injury. Osteoporos Int 2015; 26:663–672.
263. Cury Y, Picolo G, Gutierrez VP, Ferreira SH. Pain and analgesia
: the dual effect of nitric oxide in the nociceptive system. Nitric Oxide 2011; 25:245–254.
264. Schmidtko A, Tegeder I, Geisslinger G. No NO, no pain? The role of nitric oxide and cGMP in spinal pain processing. Trends Neurosci 2009; 32:339–346.
265. Miclescu A, Gordh T. Nitric oxide and pain: ‘something old, something new’. Acta Anaesth Scand 2009; 53:1107–1120.
266. Jain NK, Patil CS, Singh A, Kulkarni SK. Sildenafil, a phosphodiesterase-5 inhibitor, enhances the antinociceptive effect of morphine. Pharmacology 2003; 67:150–156.
267. Rocha FA, Silva FS Jr, Leite AC, et al. Tadalafil analgesia
in experimental arthritis involves suppression of intra-articular TNF release. Br J Pharmacol 2011; 164 (2b):828–835.
268. Huang LJ, Yoon MH, Choi JI, et al. Effect of sildenafil on neuropathic pain
and hemodynamics in rats. Yonsei Med J 2010; 51:82–87.
270. Serafim RA, Primi MC, Trossini GH, Ferreira EI. Nitric oxide: state of the art in drug design. Curr Med Chem 2012; 19:386–405.
271. Romero-Sandoval EA, Curros-Criado MM, Gaitan G, et al. Nitroparacetamol (NCX-701) and pain: first in a series of novel analgesics. CNS Drug Rev 2007; 13:279–295.
272. Lauretti GR, Perez MV, Reis MP, Pereira NL. Double-blind evaluation of transdermal nitroglycerine as adjuvant to oral morphine for cancer pain management. J Clin Anesth 2002; 14:83–86.
273. Lauretti GR, Lima IC, Reis MP, et al. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology 1999; 90:1528–1533.